DK2447283T3 - Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 (alk-1) - Google Patents
Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 (alk-1) Download PDFInfo
- Publication number
- DK2447283T3 DK2447283T3 DK12152953.1T DK12152953T DK2447283T3 DK 2447283 T3 DK2447283 T3 DK 2447283T3 DK 12152953 T DK12152953 T DK 12152953T DK 2447283 T3 DK2447283 T3 DK 2447283T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- antigen
- alk
- nucleic acid
- human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (28)
1. Neutraliserende anti-ALK-1-monoklonalt antistof eller antigenbindende del deraf, hvor antistoffet eller den antigenbindende del kryds-konkurrerer om at binde til ALK-1 med et antistof omfattende: a. et variabelt domæne med tung kæde med SEQ ID NO: 6 og et variabelt domæne med let kæde med SEQ ID NO: 8; eller b. aminosyresekvensen af det variable domæne med tung kæde, der er kodet af nukleotidsekvensen af det indlæg, der befinder sig i klonen deponeret under ATCC-accessionsnummer PTA-6864, og aminosyresekvensen af det variable domæne med let kæde, der er kodet af nukleotidsekvensen af det indlæg, der befinder sig i klonen deponeret under ATCC-accessionsnummer PTA-6865.
2. Antistof eller antigen-bindende del ifølge krav 1, hvor antistoffet omfatter: a. en tung kæde, som benytter en human VH 4-31-kimbanesekvens; og b. en let kæde, som benytter en human VK A27-kimbanesekvens.
3. Antistof eller antigen-bindende del ifølge krav 2, hvor aminosyresekvensen med den tunge kæde er mindst 90 % identisk med aminosyresekvensen kodet af den humane Vh 4-31-kimbanesekvens, og hvor aminosyresekvensen med den lette kæde er mindst 90 % identisk med aminosyresekvensen kodet af den humane VK A27-kimbanesekvens.
4. Antistof eller antigenbindende del ifølge et af kravene 1-3, hvor antistoffet omfatter et VH-domæne, som er mindst 90 % identisk med aminosyresekvensen ifølge SEQ ID NO: 6.
5. Antistof eller antigenbindende del ifølge et af kravene 1-3, hvor antistoffet omfatter et VL-domæne, som er mindst 90 % identisk med aminosyresekvensen ifølge SEQ ID NO: 8.
6. Antistof eller antigenbindende del ifølge et af kravene 1-5, hvor antistoffet omfatter et VH-domæne, som er mindst 90 % identisk med aminosyresekvensen ifølge SEQ ID NO: 6 og et VL-domæne, som er mindst 90 % identisk med aminosyresekvensen ifølge SEQ ID NO: 8.
7. Antistof eller antigenbindende del ifølge et af kravene 1-5, hvor antistoffet omfatter et Vn-domæne, som er mindst 95 % identisk med aminosyresekvensen ifølge SEQ ID NO: 6 og et Vi_-domaene, som er mindst 95 % identisk med aminosyresekvensen ifølge SEQ ID NO: 8.
8. Antistof eller antigenbindende del ifølge et af kravene 1-5, hvor antistoffet omfatter et Vn-domæne, som er mindst 99 % identisk med aminosyresekvensen ifølge SEQ ID NO: 6 og et Vi_-donnæne, som er mindst 99 % identisk med aminosyresekvensen ifølge SEQ ID NO: 8.
9. Antistof ifølge et af kravene 1-8, hvor antistoffet er et IgG-molekyle, eller er afledt deraf.
10. Antistof ifølge krav 9, hvor antistoffet er et lgG1- eller lgG2-molekyle.
11. Antistof eller antigenbindende del ifølge et af kravene 1-10, hvor antistoffet eller den antigenbindende del er derivatiseret eller forbundet med et andet molekyle.
12. Antistof eller antigenbindende del ifølge krav 11, hvor molekylet er et andet antistof, et påvisningsmiddel, en label, et cytotoksisk middel, et farmaceutisk middel, et peptid eller et protein.
13. Isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og et isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12; eller et isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12.
14. Vektor omfattende et nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og en vektor omfattende et nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigen-bindende del ifølge et af kravene 1-12, hvor hver vektor omfatter en ekspressionskontrolsekvens, der er operabelt forbundet med nukleinsyremolekylet; eller en vektor omfattende et nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og en nu-kleotidsekvens, der koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12, hvor vektoren omfatter en ekspressionskontrolsekvens, der er operabelt forbundet med nukleinsyremolekylet.
15. Værtscelle omfattende a. et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12; b. et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og en nukleotidsekvens, som koder den lette kæde af antistoffet eller den antigenbindende del ifølge et af kravene 1 -12; a. en vektor omfattende et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og en vektor omfattende et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12, hvor hver vektor omfatter en ekspressionskontrolsekvens, der er operabelt forbundet med nukleinsyremolekylet; eller d. en vektor omfattende et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og en nukleotidsekvens, som koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12, hvor vektoren omfatter en ekspressionskontrolsekvens, der er operabelt forbundet med nukleinsyremolekylet.
16. Farmaceutisk sammensætning omfattende antistoffet eller den antigenbindende del ifølge et af kravene 1-12 og en fysiologisk acceptabel bærer.
17. Anvendelse af antistoffet eller den antigenbindende del ifølge et af kravene 1-12 eller den farmaceutiske sammensætning ifølge krav 16 til fremstilling af et medikament.
18. Antistof eller den antigenbindende del ifølge et af kravene 1-12 eller en farmaceutisk sammensætning ifølge krav 16 til anvendelse inden for behandling.
19. Anvendelse af antistoffet eller den antigen-bindende del ifølge et af kravene 1-12 eller den farmaceutiske sammensætning ifølge krav 16 til fremstilling af et medikament til behandling af kræft, aldersrelateret makulær degeneration, diabetisk blindhed, endometriose, okulær neovaskularisation, psoriasis eller rheumatoid arthritis i et pattedyr.
20. Antistof eller antigen-bindende del ifølge et af kravene 1-12 eller farmaceutisk sammensætning ifølge krav 16 til anvendelse ved behandling af kræft, aldersrelateret makulær degeneration, diabetisk blindhed, endometriose, okulær neovaskularisation, psoriasis eller rheumatoid arthritis i et pattedyr.
21. Anvendelse af: a. et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12; eller b. et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og en nukleotidsekvens, som koder den lette kæde af antistoffet eller den antigenbindende del ifølge et af kravene 1 -12; til fremstilling af et medikament.
22. Nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og et nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigen-bindende del ifølge et af kravene 1-12, eller et nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og en nukleotidsekvens, der koder den lette kæde af antistoffet eller den antigen-bindende del ifølge et af kravene 1-12; til anvendelse ved behandling.
23. Anvendelse af: a. et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12; eller b. et nukleinsyremolekyle omfattende en nukleotidsekvens, som koder den tunge kæde, og en nukleotidsekvens, som koder den lette kæde af antistoffet eller den antigenbindende del ifølge et af kravene 1-12; til fremstilling af et medikament til behandling af kræft, aldersrelateret maku-lær degeneration, diabetisk blindhed, endometriose, okulær neovaskularisa-tion, psoriasis eller reumatoid artritis i et pattedyr.
24. Isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og et isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12; eller et isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigenbindende del ifølge et af kravene 1-12; til anvendelse ved behandling af kræft, aldersrelateret makulær degeneration, diabetisk blindhed, endometriose, okulær neovaskularisation, psoriasis eller reumatoid artritis i et pattedyr.
25. Antistof, antigen-bindende del eller farmaceutisk sammensætning ifølge krav 20 til anvendelse ved behandling af kræft, eller anvendelse ifølge krav 19 til fremstilling af et medikament til behandling af kræft, hvor kræften er kutan eller intraokulær melanom, mesotheliom, renal cellecarcinom, brystkræft, hoved- og halskræft, en primær eller sekundær hjernetumor, carcinom i cervix, kræft i urinrøret, prostatakræft, pancreaskræft, testikel kræft, hepato-biliær kræft, kræft i galdegangene, kræft i galdevejene, kolorektal kræft, blærekræft, æggestokkræft, lungekræft, ikke småcellet lungekræft, småcellet lungekræft, tarmkræft, rektalkræft eller kræft i analregionen.
26. Anvendelse af et monoklonalt antistof omfattende en aminosyresekvens med tung kæde med SEQ ID NO: 2 og en aminosyresekvens med let kæde med SEQ ID NO: 4 til fremstilling af et medikament til behandling af hepato- biliær kræft i et pattedyr.
27. Monoklonalt antistof omfattende en aminosyresekvens med tung kæde med SEQ ID NO: 2 og en aminosyresekvens med let kæde med SEQ ID NO: 4 til fremstilling ved behandling af hepatobiliær kræft i et pattedyr.
28. Antistof, antigen-bindende del eller farmaceutisk sammensætning til anvendelse ifølge et af kravene 20, 25 og 27, isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigen-bindende del ifølge et af kravene 1-12, eller isoleret nukleinsyremolekyle omfattende en nukleotidsekvens, der koder den tunge kæde, og en nukleotidsekvens, der koder den lette kæde af et antistof eller en antigen-bindende del ifølge et af kravene 1-12, til anvendelse ifølge krav 24, eller anvendelse ifølge et af kravene 19, 23, 25 og 26; hvor pattedyret er et menneske.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71529205P | 2005-09-07 | 2005-09-07 | |
EP06824915.0A EP1933871B1 (en) | 2005-09-07 | 2006-09-06 | Human monoclonal antibodies to activin receptor-like kinase-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2447283T3 true DK2447283T3 (da) | 2015-08-31 |
Family
ID=37906640
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06824915.0T DK1933871T3 (da) | 2005-09-07 | 2006-09-06 | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
DK15169743.0T DK2960253T3 (da) | 2005-09-07 | 2006-09-06 | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
DK12152953.1T DK2447283T3 (da) | 2005-09-07 | 2006-09-06 | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 (alk-1) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06824915.0T DK1933871T3 (da) | 2005-09-07 | 2006-09-06 | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
DK15169743.0T DK2960253T3 (da) | 2005-09-07 | 2006-09-06 | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
Country Status (41)
Country | Link |
---|---|
US (3) | US7537762B2 (da) |
EP (4) | EP2447283B1 (da) |
JP (3) | JP5161777B2 (da) |
KR (3) | KR101390127B1 (da) |
CN (2) | CN101517068B (da) |
AP (2) | AP2723A (da) |
AR (2) | AR055152A1 (da) |
AU (1) | AU2006297571B2 (da) |
BR (1) | BRPI0615766A2 (da) |
CA (1) | CA2621371C (da) |
CL (1) | CL2010000096A1 (da) |
CR (3) | CR9819A (da) |
CY (1) | CY1120794T1 (da) |
DK (3) | DK1933871T3 (da) |
DO (1) | DOP2006000195A (da) |
EA (2) | EA018453B1 (da) |
ES (3) | ES2421146T3 (da) |
GE (1) | GEP20125398B (da) |
GT (1) | GT200600406A (da) |
HK (2) | HK1169999A1 (da) |
HN (1) | HN2006031275A (da) |
HU (2) | HUE025608T2 (da) |
IL (2) | IL189642A (da) |
LT (1) | LT2960253T (da) |
MA (1) | MA29843B1 (da) |
ME (1) | ME00501B (da) |
MY (1) | MY164457A (da) |
NL (1) | NL1032452C2 (da) |
NO (1) | NO20081718L (da) |
NZ (1) | NZ566774A (da) |
PE (1) | PE20080035A1 (da) |
PL (3) | PL2960253T3 (da) |
PT (3) | PT2960253T (da) |
RS (1) | RS54393B1 (da) |
SI (3) | SI2447283T1 (da) |
TN (1) | TNSN08080A1 (da) |
TW (5) | TWI389919B (da) |
UA (1) | UA94060C2 (da) |
UY (1) | UY29783A1 (da) |
WO (1) | WO2007040912A2 (da) |
ZA (1) | ZA200802971B (da) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
US7897581B2 (en) * | 2005-02-24 | 2011-03-01 | Massachusetts Eye & Ear Infirmary | Methods and compounds for promoting vessel regression |
PL2960253T3 (pl) * | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
US8084027B2 (en) * | 2006-02-10 | 2011-12-27 | Nerviano Medical Sciences S.R.L. | Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic |
AU2012265564B2 (en) * | 2006-09-08 | 2016-05-26 | Amgen Inc | Anti-activin A antibodies and uses thereof |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
AU2016247166B2 (en) * | 2006-11-02 | 2018-09-27 | Acceleron Pharma Inc. | ALK1 receptor and ligand antagonists and uses thereof |
BRPI0717964A2 (pt) * | 2006-11-02 | 2013-12-17 | Acceleron Pharma Inc | Receptor e antagonistas de ligante da alk1 e usos dos mesmos. |
US10059756B2 (en) | 2006-11-02 | 2018-08-28 | Acceleron Pharma Inc. | Compositions comprising ALK1-ECD protein |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
PE20081899A1 (es) * | 2007-04-02 | 2009-01-26 | Pfizer | Anticuerpos anti-ige |
ITTV20070126A1 (it) | 2007-07-16 | 2009-01-17 | Luca Toncelli | Procedimento ed apparecchiatura per la fabbricazione di lastre ad effet-to venato |
EP2217261B1 (en) * | 2007-11-09 | 2015-10-07 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist compositions and methods of use |
EP2918605A1 (en) * | 2007-11-12 | 2015-09-16 | U3 Pharma GmbH | Axl antibodies |
MX2010008099A (es) * | 2008-01-28 | 2010-08-04 | Medimmune Ltd | Anticuerpos y angiopoyetina-2 estabilizados y sus usos. |
US7855564B2 (en) * | 2008-02-14 | 2010-12-21 | Delaware Capital Formation, Inc. | Acoustic wave device physical parameter sensor |
US20110110944A1 (en) * | 2008-04-25 | 2011-05-12 | Morphosys Ag | Anti-alk1 antibodies and uses thereof |
KR20180029111A (ko) * | 2008-05-02 | 2018-03-19 | 악셀레론 파마 인코포레이티드 | 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 alk1 길항제 기재의 방법 및 조성물 |
EP2291401A2 (en) * | 2008-05-15 | 2011-03-09 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
EA201791940A3 (ru) | 2008-11-26 | 2018-04-30 | Амген Инк. | Варианты полипептидов рецептора iib активина и их использование |
WO2010126169A1 (ja) * | 2009-04-30 | 2010-11-04 | 協和発酵キリン株式会社 | Alk1阻害剤を有効成分とする血管障害を抑制するための医薬組成物 |
GB0915515D0 (en) * | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
US20150359850A1 (en) | 2009-11-25 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
JP2013515754A (ja) * | 2009-12-29 | 2013-05-09 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規な抗体製剤 |
KR102044948B1 (ko) * | 2010-06-25 | 2019-11-14 | 백시바디 에이에스 | 동종이합체 단백질 구조물 |
SG10201605027XA (en) | 2011-12-19 | 2016-08-30 | Amgen Inc | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
TW201341401A (zh) | 2012-01-09 | 2013-10-16 | Covx Technologies Ireland Ltd | 突變抗體及其共軛 |
EP2836514A4 (en) | 2012-04-13 | 2015-12-30 | Childrens Medical Center | TIKI INHIBITORS |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
EP2787006B1 (en) * | 2013-04-02 | 2018-02-28 | Miltenyi Biotec GmbH | Anti-CD8 antibody which binding is Ca2+ dependent |
JP6668241B2 (ja) | 2013-09-05 | 2020-03-18 | アムジエン・インコーポレーテツド | 予測可能で、一貫性のある、且つ再現可能な糖型特性を示すFc含有分子 |
EP3467501B1 (en) | 2014-05-16 | 2020-11-04 | Amgen Inc. | Assay for detecting th1 and th2 cell populations |
WO2016054053A2 (en) * | 2014-09-29 | 2016-04-07 | Duke University | Hiv-1 antibodies and uses thereof (adcc and bispecific abs) |
GB201503438D0 (en) | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
KR20180014714A (ko) | 2015-06-05 | 2018-02-09 | 노파르티스 아게 | 골 형태형성 단백질 9 (bmp9)를 표적화하는 항체 및 그에 대한 방법 |
KR101983013B1 (ko) * | 2015-09-25 | 2019-05-28 | 동우 화인켐 주식회사 | 필름 터치 센서 및 그 제조 방법 |
JP2017077830A (ja) * | 2015-10-21 | 2017-04-27 | Kyb株式会社 | 電動パワーステアリング装置 |
EP3413912A4 (en) * | 2016-02-11 | 2019-09-25 | The Johns Hopkins University | COMPOSITIONS AND METHODS FOR TARGETING SIGNALING OF ACTIVIN TO TREAT CANCER |
RU2615908C1 (ru) * | 2016-05-16 | 2017-04-11 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ моделирования лимфогенного и гематогенного метастазирования мышиной меланомы В16 у белых нелинейных крыс |
SG11201900027XA (en) * | 2016-08-05 | 2019-02-27 | Medimmune Llc | Anti-o2 antibodies and uses thereof |
JP7160484B2 (ja) | 2016-10-19 | 2022-10-25 | メディミューン,エルエルシー | 抗o1抗体およびその使用 |
EP3596225A1 (en) | 2017-03-14 | 2020-01-22 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
EA202092286A1 (ru) | 2018-03-26 | 2021-03-18 | Эмджен Инк. | Общие афукозилированные гликоформы антител, полученные в культуре клеток |
EP4034556A1 (en) | 2019-09-26 | 2022-08-03 | Amgen Inc. | Methods of producing antibody compositions |
US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
WO2022081824A1 (en) | 2020-10-15 | 2022-04-21 | Amgen Inc. | Relative unpaired glycans in antibody production methods |
AR126089A1 (es) | 2021-06-07 | 2023-09-13 | Amgen Inc | Uso de fucosidasa para controlar el nivel de afucosilación de proteínas glucosiladas |
CN115746142A (zh) * | 2021-09-03 | 2023-03-07 | 开拓药业(广东)有限公司 | 抗alk-1/抗vegf双特异性抗体及其应用 |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US4959455A (en) * | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
JPH0341802A (ja) | 1989-07-07 | 1991-02-22 | Ngk Spark Plug Co Ltd | 温度補償型マイクロ波ストリップラインフィルタ |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ES2330052T3 (es) | 1991-03-01 | 2009-12-03 | Dyax Corporation | Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas. |
EP0580737B1 (en) | 1991-04-10 | 2004-06-16 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
DE69334255D1 (de) * | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US7592428B1 (en) * | 1992-11-17 | 2009-09-22 | Ludwig Institute For Cancer Research | Antibodies which bind specifically to activin receptor like kinases |
DE69332779T2 (de) * | 1992-11-17 | 2003-10-23 | Ludwig Inst For Cancer Res Pad | Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen |
US6692925B1 (en) * | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
EP0804070B1 (en) | 1993-03-09 | 2000-05-24 | Genzyme Corporation | Process of isolation of proteins from milk |
US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
US5466823A (en) * | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5608082A (en) | 1994-07-28 | 1997-03-04 | Agouron Pharmaceuticals, Inc. | Compounds useful as antiproliferative agents and GARFT inhibitors |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
WO1996033266A1 (en) | 1995-04-21 | 1996-10-24 | Cell Genesys, Inc. | Generation of large genomic dna deletions |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
AU709991B2 (en) * | 1995-08-14 | 1999-09-09 | Creative Biomolecules, Inc. | Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
US5663272A (en) * | 1995-12-22 | 1997-09-02 | Bayer Corporation | Allophanate-modified diphenylmethane diisocyanates and processes for their production and use |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) * | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US6180651B1 (en) | 1996-04-04 | 2001-01-30 | Bristol-Myers Squibb | Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics |
DE69739003D1 (de) | 1996-04-12 | 2008-10-30 | Searle Llc | Substituierte Benzensulfonamid-Derivate als Wirkstoff-Vorläufer von COX-2 Inhibitoren |
DE19616523A1 (de) * | 1996-04-25 | 1997-11-06 | Basf Ag | Polymerisationskatalysatoren mit beta-Diketiminat-Liganden |
JPH11512750A (ja) * | 1996-06-27 | 1999-11-02 | ファイザー インク. | 2―(2―オキソ―エチリデン)―イミダゾリジン―4―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法 |
EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
PL187848B1 (pl) | 1996-07-18 | 2004-10-29 | Merck Frosst Canada Inc | Podstawione pirydyny, kompozycja farmaceutyczna, podstawione pirydyny jako selektywne inhibitory cyklooksygenazy-2 oraz zastosowanie podstawionych pirydyn |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2239393T3 (es) | 1997-05-07 | 2005-09-16 | Sugen, Inc. | Derivados de 2-indolinona utilizados como moduladores de la actividad de la proteina-quinasa. |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
JP2002501532A (ja) | 1997-05-30 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 新規血管形成阻害薬 |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
CN101328186A (zh) | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
JPH11236333A (ja) * | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
EP1060193A2 (en) | 1998-03-03 | 2000-12-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
WO1999046386A1 (en) * | 1998-03-13 | 1999-09-16 | Ludwig Institute For Cancer Research | ALK-1 RESPONDS TO TGF-β AND SIGNALS THROUGH SMAD-1 AND SMAD-5 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US6395734B1 (en) | 1998-05-29 | 2002-05-28 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
ES2237125T3 (es) * | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
JP3495706B2 (ja) * | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体 |
EP1006113A1 (en) * | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
ES2340745T3 (es) | 1998-12-23 | 2010-06-08 | Pfizer Inc. | Anticuerpos monoclonales humanos contra ctla-4. |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
EP1150973B1 (en) * | 1999-02-11 | 2005-06-15 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
US5998206A (en) * | 1999-02-23 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense inhibiton of human G-alpha-12 expression |
US6586447B1 (en) * | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
DE60022383T2 (de) | 1999-11-05 | 2006-03-09 | Amada Co., Ltd., Isehara | Biegepresse und verfahren zum steuern einer bidirektionalen flüssigkeitspumpe eines hydraulikzylinders einer biegepresse |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
DE60008206T2 (de) * | 1999-11-30 | 2004-12-02 | Pfizer Products Inc., Groton | Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase |
CA2394576A1 (en) * | 1999-12-15 | 2001-06-21 | Research Development Foundation | Betaglycan as an inhibin receptor and uses thereof |
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US6584504B1 (en) * | 2000-05-26 | 2003-06-24 | Networks Associates Technology, Inc. | Method and apparatus for monitoring internet traffic on an internet web page |
DZ3407A1 (da) | 2000-06-22 | 2001-12-27 | Pfizer Prod Inc | |
AU2001229563A1 (en) | 2000-09-20 | 2002-04-02 | Human Genome Sciences, Inc. | 21 human secreted proteins |
HUP0302525A2 (hu) | 2001-01-05 | 2003-10-28 | Abgenix, Inc. | Az inzulinszerű növekedési faktor I receptor elleni ellenanyagok |
AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
CA2658221C (en) * | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
WO2003048328A2 (en) * | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
JP2005516965A (ja) * | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗muc18抗体を使用する方法 |
PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
ES2347239T3 (es) * | 2002-12-02 | 2010-10-27 | Amgen Fremont Inc. | Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos. |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
CN103087970B (zh) | 2005-02-04 | 2016-12-21 | Cp凯尔科美国公司 | 多糖粘液形成菌的靶基因缺失 |
PL2960253T3 (pl) * | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2006
- 2006-09-06 PL PL15169743T patent/PL2960253T3/pl unknown
- 2006-09-06 SI SI200631985T patent/SI2447283T1/sl unknown
- 2006-09-06 PE PE2006001075A patent/PE20080035A1/es not_active Application Discontinuation
- 2006-09-06 HN HN2006031275A patent/HN2006031275A/es unknown
- 2006-09-06 KR KR1020087006587A patent/KR101390127B1/ko active IP Right Grant
- 2006-09-06 RS RS20080103A patent/RS54393B1/en unknown
- 2006-09-06 PT PT151697430T patent/PT2960253T/pt unknown
- 2006-09-06 KR KR1020137033726A patent/KR101536506B1/ko active IP Right Grant
- 2006-09-06 HU HUE12152953A patent/HUE025608T2/en unknown
- 2006-09-06 PL PL06824915T patent/PL1933871T3/pl unknown
- 2006-09-06 UY UY29783A patent/UY29783A1/es not_active Application Discontinuation
- 2006-09-06 JP JP2008530231A patent/JP5161777B2/ja active Active
- 2006-09-06 BR BRPI0615766-1A patent/BRPI0615766A2/pt not_active IP Right Cessation
- 2006-09-06 SI SI200632285T patent/SI2960253T1/sl unknown
- 2006-09-06 LT LTEP15169743.0T patent/LT2960253T/lt unknown
- 2006-09-06 TW TW099108743A patent/TWI389919B/zh active
- 2006-09-06 CN CN200680041490.3A patent/CN101517068B/zh active Active
- 2006-09-06 MY MYPI20080556A patent/MY164457A/en unknown
- 2006-09-06 ES ES06824915T patent/ES2421146T3/es active Active
- 2006-09-06 NL NL1032452A patent/NL1032452C2/nl active Search and Examination
- 2006-09-06 ZA ZA200802971A patent/ZA200802971B/xx unknown
- 2006-09-06 ES ES15169743.0T patent/ES2681656T3/es active Active
- 2006-09-06 TW TW103116433A patent/TWI541253B/zh not_active IP Right Cessation
- 2006-09-06 DO DO2006000195A patent/DOP2006000195A/es unknown
- 2006-09-06 KR KR1020137007712A patent/KR101536487B1/ko active IP Right Grant
- 2006-09-06 AU AU2006297571A patent/AU2006297571B2/en not_active Ceased
- 2006-09-06 DK DK06824915.0T patent/DK1933871T3/da active
- 2006-09-06 TW TW101141374A patent/TWI453218B/zh active
- 2006-09-06 PT PT121529531T patent/PT2447283E/pt unknown
- 2006-09-06 ME MEP-2008-812A patent/ME00501B/me unknown
- 2006-09-06 US US11/517,530 patent/US7537762B2/en active Active
- 2006-09-06 CA CA2621371A patent/CA2621371C/en active Active
- 2006-09-06 GE GEAP200610627A patent/GEP20125398B/en unknown
- 2006-09-06 ES ES12152953.1T patent/ES2546069T3/es active Active
- 2006-09-06 PL PL12152953T patent/PL2447283T3/pl unknown
- 2006-09-06 AP AP2008004388A patent/AP2723A/xx active
- 2006-09-06 WO PCT/US2006/035096 patent/WO2007040912A2/en active Application Filing
- 2006-09-06 GT GT200600406A patent/GT200600406A/es unknown
- 2006-09-06 EP EP12152953.1A patent/EP2447283B1/en active Active
- 2006-09-06 TW TW095132933A patent/TWI370137B/zh active
- 2006-09-06 UA UAA200804286A patent/UA94060C2/ru unknown
- 2006-09-06 EP EP18170945.2A patent/EP3381945B1/en active Active
- 2006-09-06 EP EP15169743.0A patent/EP2960253B1/en active Active
- 2006-09-06 PT PT68249150T patent/PT1933871E/pt unknown
- 2006-09-06 EP EP06824915.0A patent/EP1933871B1/en active Active
- 2006-09-06 TW TW103138817A patent/TWI569807B/zh active
- 2006-09-06 NZ NZ566774A patent/NZ566774A/en unknown
- 2006-09-06 HU HUE15169743A patent/HUE038941T2/hu unknown
- 2006-09-06 AP AP2013006963A patent/AP2013006963A0/xx unknown
- 2006-09-06 DK DK15169743.0T patent/DK2960253T3/da active
- 2006-09-06 CN CN201611215981.7A patent/CN107056943B/zh active Active
- 2006-09-06 EA EA200800759A patent/EA018453B1/ru not_active IP Right Cessation
- 2006-09-06 SI SI200631626T patent/SI1933871T1/sl unknown
- 2006-09-06 EA EA201300320A patent/EA201300320A1/ru unknown
- 2006-09-06 AR ARP060103884A patent/AR055152A1/es not_active Application Discontinuation
- 2006-09-06 DK DK12152953.1T patent/DK2447283T3/da active
-
2008
- 2008-02-21 TN TNP2008000080A patent/TNSN08080A1/en unknown
- 2008-02-21 IL IL189642A patent/IL189642A/en not_active IP Right Cessation
- 2008-03-14 CR CR9819A patent/CR9819A/es unknown
- 2008-04-01 MA MA30800A patent/MA29843B1/fr unknown
- 2008-04-07 NO NO20081718A patent/NO20081718L/no not_active Application Discontinuation
-
2009
- 2009-03-12 US US12/402,854 patent/US8080646B2/en active Active
-
2010
- 2010-02-04 CL CL2010000096A patent/CL2010000096A1/es unknown
-
2011
- 2011-10-26 US US13/282,065 patent/US9221915B2/en active Active
-
2012
- 2012-03-01 IL IL218429A patent/IL218429A0/en unknown
- 2012-07-02 JP JP2012148146A patent/JP5833978B2/ja active Active
- 2012-10-26 HK HK12110733.7A patent/HK1169999A1/xx not_active IP Right Cessation
-
2013
- 2013-07-19 CR CR20130351A patent/CR20130351A/es unknown
-
2014
- 2014-05-22 CR CR20140239A patent/CR20140239A/es unknown
- 2014-08-13 JP JP2014164638A patent/JP5947840B2/ja active Active
-
2016
- 2016-06-27 HK HK16107449.4A patent/HK1219488A1/zh not_active IP Right Cessation
- 2016-12-20 AR ARP160103944A patent/AR107003A2/es unknown
-
2018
- 2018-08-09 CY CY181100829T patent/CY1120794T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2447283T3 (da) | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 (alk-1) | |
AU2014218362B2 (en) | Human Monoclonal Antibodies to Activin Receptor-like Kinase-1 | |
AU2012203432B2 (en) | Human Monoclonal Antibodies to Activin Receptor-like Kinase-1 | |
AU2013205016B2 (en) | Human Monoclonal Antibodies to Activin Receptor-like Kinase-1 |